Anesthetic management of lung transplantation in a patient with end-stage COVID-19 pneumonia

Since the first human procedure in 1963, lung transplantation has become the gold standard treatment of a variety of end-stage lung diseases. With over 4000 lung transplants performed in 2015 and steadily improving survival rates over the past three decades, anesthetic management of patients undergoing lung transplant can significantly contribute to patient outcomes. Anesthesia care for lung transplantation can be both complex and clinically challenging. Anesthesiologists taking part in these procedures need to have specific skills regarding thoracic and cardiac anesthesia. There are both technical and physiological challenges, such as achieving adequate lung isolation and oxygenation, interpretation and use of transesophageal echocardiography, and the management of respiratory and myocardial impairments. This chapter provides an overview of these perioperative anesthetic management considerations utilizing a problem-based format.

Download Full-text

Faculty Opinions recommendation of Antireflux surgery preserves lung function in patients with gastroesophageal reflux disease and end-stage lung disease before and after lung transplantation.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718000906.793475046 ◽

2013 ◽

Author(s):

Keith Meyer

Keyword(s):

Gastroesophageal Reflux Disease ◽

Lung Function ◽

Gastroesophageal Reflux ◽

Lung Transplantation ◽

Lung Disease ◽

Reflux Disease ◽

Antireflux Surgery ◽

Before And After ◽

End Stage

Download Full-text

Lung transplantation for silicosis and recovery: an Australian case study

British Journal of Nursing ◽

10.12968/bjon.2021.30.3.178 ◽

2021 ◽

Vol 30 (3) ◽

pp. 178-183

Author(s):

Kate McEwen ◽

Lyndell Brodie

Keyword(s):

Lung Transplantation ◽

Medication Management ◽

Social Situation ◽

Bilateral Lung Transplantation ◽

Transplantation Surgery ◽

Australian Case ◽

Bilateral Lung ◽

End Stage

Lung transplantation is a well-established treatment for a variety of end-stage pulmonary diseases. However, the journey of a lung transplant recipient is complex and multifaceted. Silicosis is a rare indication for lung transplantation, but no other treatment is yet available for this disease in its end stages. This Australian case study presents a 52-year-old man with silicosis who received bilateral lung transplantation. The patient was frequently noncompliant with noninvasive ventilation therapy and experienced the complication of type 2 respiratory failure. Patient education and support provided, particularly around medication management following transplantation surgery, are discussed here. The patient's social situation and its implications for both him and his family are also considered.

Download Full-text

Model for End-Stage Liver Disease (MELD) Score Among Patients Qualified For Lung Transplantation With End-Stage Lung Diseases With Particular Consideration of Median Pulmonary Artery Pressure

Transplantation Proceedings ◽

10.1016/j.transproceed.2020.03.043 ◽

2020 ◽

Vol 52 (7) ◽

pp. 2128-2132

Author(s):

Tomasz Stącel ◽

Mirosław Nęcki ◽

Magdalena Latos ◽

Maciej Urlik ◽

Remigiusz Antończyk ◽

...

Keyword(s):

Liver Disease ◽

Pulmonary Artery ◽

Lung Transplantation ◽

Pulmonary Artery Pressure ◽

Lung Diseases ◽

Meld Score ◽

Artery Pressure ◽

End Stage Liver Disease ◽

End Stage

Download Full-text

Recent advances in lung transplantation

F1000Research ◽

10.12688/f1000research.15393.1 ◽

2018 ◽

Vol 7 ◽

pp. 1684 ◽

Cited By ~ 13

Author(s):

Keith C Meyer

Keyword(s):

Lung Transplantation ◽

Primary Graft Dysfunction ◽

Graft Dysfunction ◽

Donor Pool ◽

Post Transplant ◽

Antibody Mediated Rejection ◽

The Past ◽

End Stage ◽

Transplant Complications

Lung transplantation can improve quality of life and prolong survival for individuals with end-stage lung disease, and many advances in the realms of both basic science and clinical research aspects of lung transplantation have emerged over the past few decades. However, many challenges must yet be overcome to increase post-transplant survival. These include successfully bridging patients to transplant, expanding the lung donor pool, inducing tolerance, and preventing a myriad of post-transplant complications that include primary graft dysfunction, forms of cellular and antibody-mediated rejection, chronic lung allograft dysfunction, and infections. The goal of this manuscript is to review salient recent and evolving advances in the field of lung transplantation.

Download Full-text